Hematopoietic cell transplants in autoimmunity

Israel Medical Association Journal

Volumn 11, Issue 10, 2009, Pages 629-632

  De Carvalho, Jozélio Freire ^a   Pereira, Rosa Maria Rodrigues ^a   Gershwin, M Eric ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmune diseases; Hematopoietic cell transplant; Refractory diseases; Stem cell transpalntation; Treatment

Indexed keywords

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BEHCET DISEASE; CELIAC DISEASE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CROHN DISEASE; CYTOPENIA; DERMATOMYOSITIS; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE DELIVERY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; MYELOABLATIVE CONDITIONING; PATIENT CARE; PATIENT SAFETY; PEMPHIGUS FOLIACEUS; POLYMYOSITIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; SYSTEMIC VASCULITIS; TREATMENT OUTCOME;

AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS;

EID: 70350678787     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2008; 59: 1796-1804
2. Gisondi P, Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev 2007; 6: 515-519 (Pubitemid 47374611)
3. Iaccarino L, Rampudda M, Canova M, Della Libera S, Sarzi-Puttinic P, Doria A. Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev 2007; 6: 190-195 (Pubitemid 46187338)
4. Zeng C, Zhen Y, Shu SA, et al. The influence of cyclosporin A on lymphocyte attenuator expression. J Autoimmun 2007; 28: 234-244 (Pubitemid 46754769)
5. Abraham M, Karni A, Dembinsky A, et al. In vitro induction of regulatory T cells by anti-CD3 antibody in humans. J Autoimmun 2008; 30: 21-28
6. Atzeni F, Doria A, Carrabba M, Turiel M, Sarzi-Puttini P. Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmun Rev 2007; 6: 529-536 (Pubitemid 47374618)
7. Caporali R, Pallavicini FB, Filippini M, et al. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 2009; 8: 274-280
8. Ingegnoli F, Fantini F, Favalli EG, et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun 2008; 31: 175-179
9. Punzi L, Podswiadek M, Sfriso P, Oliviero F, Fiocco U, Todesco S. Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis. Autoimmun Rev 2007; 6: 524-528 (Pubitemid 47374613)
10. Valesini G, Iannuccelli C, Marocchi E, Pascoli L, Scalzi V, Di Franco M. Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev 2007; 7: 35-41. (Pubitemid 47633389)
11. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-2376 (Pubitemid 44204996)
12. Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun 2008; 30: 90-98
13. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev 2008; 8: 144-146
14. Nannini C, Cantini F, Niccoli L, et al. Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? Arthritis Rheum 2009; 61: 801-812
15. Deane S, Meyers FJ, Gershwin ME. On reversing the persistence of memory: hematopoietic stem cell transplant for autoimmune disease in the first ten years. J Autoimmun 2008; 30: 180-196
16. Farge D, Nash R, Laar JM. Autologous stem cell transplantation for systemic sclerosis. Autoimmunity 2008; 28: 1.
17. Brinkman DM, de Kleer IM, ten Cate R, et al. Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial. Arthritis Rheum 2007; 56: 2410-2421
18. Burt RK, Traynor A, Statkute L, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006; 295: 527-535 (Pubitemid 43200347)
19. Voltarelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007; 297: 1568-1576 (Pubitemid 46588370)
20. Gershwin ME. Bone marrow transplantation, refractory autoimmunity and the contributions of Susumu Ikehara. J Autoimmun 2008; 30: 105-107
21. Ikehara S. A novel method of bone marrow transplantation (BMT) for intractable autoimmune diseases. J Autoimmun 2008; 30: 108-115
22. Payne N, Siatskas C, Bernard CC. The promise of stem cell and regenerative therapies for multiple sclerosis. J Autoimmun 2008; 31: 288-294
23. Tsukamoto H, Nagafuji K, Horiuchi T, et al. A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. Ann Rheum Dis 2006; 65: 508-514
24. Ozawa K, Sato K, Oh I, et al. Cell and gene therapy using mesenchymal stem cells (MSCs). J Autoimmun 2008; 30: 121-127
25. Portaccio E, Amato MP, Siracusa G, et al. Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two cases. Mult Scler 2007; 13: 676-678 (Pubitemid 46939538)
26. Remenyi P, Masszi T, Borbenyi Z, Soos J, Siklos L, Engelhardt JI. CIDP cured by allogeneic hematopoietic stem cell transplantation. Eur J Neurol 2007; 14: e1-2.
27. Rezvani AR, Storb RF. Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation. J Autoimmun 2008; 30: 172-179
28. Sonoda Y. Immunophenotype and functional characteristics of human primitive CD34-negative hematopoietic stem cells: the significance of the intra-bone marrow injection. J Autoimmun 2008; 30: 136-144
29. Urban C, Lackner H, Sovinz P, et al. Successful unrelated cord blood transplantation in a 7-year-old boy with Evans syndrome refractory to immunosuppression and double autologous stem cell transplantation. Eur J Haematol 2006; 76: 526-530
30. Lee S. Outcomes research in hematopoietic cell transplantation. In: Blume K, Forman S, Appelbaum F, eds. Thomas's Hematopoietic Cell Transplantation. 3rd edn. Malden, MA: Blackwell, 2004: 434-446
31. de Lissovoy G, Hurd D, Carter S, et al. Economic analysis of unrelated allogeneic bone marrow transplantation: results from the randomized clinical trial of T-cell depletion vs unmanipulated grafts for the prevention of graft-versus-host disease. Bone Marrow Transplant 2005; 36: 539-546 (Pubitemid 43118149)
32. Griffiths RI, Bass EB, Powe NR, Anderson GF, Goodman S, Wingard JR. Factors influencing third party payer costs for allogeneic BMT. Bone Marrow Transplant 1993; 12: 43-48 (Pubitemid 23231034)
33. Gershwin ME. The mosaic of autoimmunity. Autoimmun Rev 2008; 7: 161-163
34. Crispin JC, Tsokos GC. Transcriptional regulation of IL-2 in health and autoimmunity. Autoimmun Rev 2009; 8: 190-195
35. Doria A, Zampieri S, Sarzi-Puttini P. Exploring the complex relationships between infections and autoimmunity. Autoimmun Rev 2008; 8: 89-91.
36. Meroni PL, Shoenfeld Y. Predictive, protective, orphan autoantibodies: the example of anti-phospholipid antibodies. Autoimmun Rev 2008; 7: 585-587
37. Toplak N, Kveder T, Trampus-Bakija A, Subelj V, Cucnik S, Avcin T. Autoimmune response following annual influenza vaccination in 92 apparently healthy adults. Autoimmun Rev 2008; 8: 134-138
38. Fritzler MJ. Challenges to the use of autoantibodies as predictors of disease onset, diagnosis and outcomes. Autoimmun Rev 2008; 7: 616-620
39. Mackay IR, Leskovsek NV, Rose NR. Cell damage and autoimmunity: a critical appraisal. J Autoimmun 2008; 30: 5-11.
40. Shoenfeld Y, Selmi C, Zimlichman E, Gershwin ME. The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun 2008; 31: 325-330